CAJ | 학술논문

目的：观察参麦开肺散治疗系统性硬化症肺间质病变的临床疗效。方法2010年3月—2014年3月收治系统性硬化症肺间质病变患者65例，随机分为治疗组和对照组，治疗组33例，对照组32例。2组均给予基础常规治疗，治疗组另给予参麦开肺散，对照组另给予罗红霉素、乙酰半胱氨酸泡腾片。12周为1个疗程。1个疗程后观察2组疗效，并检测2组治疗前后中医证候积分，6分钟步行距离（6MWT）、HRCT观察肺内磨玻璃样病变情况，肺功能[用力肺活量（ FVC）、第1秒用力呼气容积（ FEV1）、FEV1／FVC]改善情况。结果2组实际完成试验各30例，治疗组总有效率为93垐．33％（28／30）高于对照组的70．00％（21／30），差异有统计学意义（χ2＝5．455， P ＜0．05）。与治疗前比较，2组治疗后中医证候积分、6MWT、HRCT观察肺内磨玻璃样病变情况，肺功能改善均改善（ P ＜0．01或P ＜0．05），且治疗组气短、咳嗽等中医证候积分及肺功能改善优于对照组，差异均有统计学意义（ P ＜0．01或P ＜0．05）。结论参麦开肺散治疗系统性硬化症肺间质病变疗效确切。
목적：관찰삼맥개폐산치료계통성경화증폐간질병변적림상료효。방법2010년3월—2014년3월수치계통성경화증폐간질병변환자65례，수궤분위치료조화대조조，치료조33례，대조조32례。2조균급여기출상규치료，치료조령급여삼맥개폐산，대조조령급여라홍매소、을선반광안산포등편。12주위1개료정。1개료정후관찰2조료효，병검측2조치료전후중의증후적분，6분종보행거리（6MWT）、HRCT관찰폐내마파리양병변정황，폐공능[용력폐활량（ FVC）、제1초용력호기용적（ FEV1）、FEV1／FVC]개선정황。결과2조실제완성시험각30례，치료조총유효솔위93자．33％（28／30）고우대조조적70．00％（21／30），차이유통계학의의（χ2＝5．455， P ＜0．05）。여치료전비교，2조치료후중의증후적분、6MWT、HRCT관찰폐내마파리양병변정황，폐공능개선균개선（ P ＜0．01혹P ＜0．05），차치료조기단、해수등중의증후적분급폐공능개선우우대조조，차이균유통계학의의（ P ＜0．01혹P ＜0．05）。결론삼맥개폐산치료계통성경화증폐간질병변료효학절。
Objective To observe the clinical effect of Shenmaikaifei powders for the treatment of pulmonary intersti-tial lesions in patients with systemic sclerosis.Methods From March 2010 to March 2014, 65 patients with systemic sclerosis and pulmonary interstitial lesions were randomly divided into treatment group and control group, 33 cases in treatment group and 32 cases in control group.2 groups were given conventional therapy, treatment group given Shenmaikaifei powders, con-trol group given roxithromycin, acetylcysteine effervescent tablets.12 weeks for 1 course.After a course of treatment, ob-served the curative effect of the two groups, and detected 2 groups'before and after treatment's TCM syndromes score, 6 mi-nutes walk distance (6MWT) , HRCT were used to observe lung ground glass like lesions, pulmonary function [ forced vital capacity ( FVC) , the forced expiratory volume in one second ( FEV1 ) , FEV1/FVC] improvement.Results Two groups had 30 cases in each group completed the experiment, treatment group's total effective rate was 93.33% (28/30), which was higher than that of the control group of 70.00% (21/30), the difference was statistically significant (χ2 =5.455, P <0.05).Compared with before treatment, after treatment in the two groups, TCM syndrome score, 6MWT, HRCT lungs glass like lesions, pulmonary function improvement were improved ( P <0.01 or P <0.05), and in the treatment group, shortness of breath, cough, TCM syndrome score, pulmonary function were better than those of the control group, the differences were statistically significant ( P <0.01 or P <0.05) .Conclusion Efficacy of the Shenmaikaifei powders for treatment of pulmo-nary interstitial lesions in patients with systemic sclerosis is good.